| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18070211 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 136 journal articles in the PubMed database | Email to a friend | | |
| Yang CH, Lin WC, Chuang CK, et al.
Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. [JOURNAL ARTICLE]
Br J Dermatol 2007 Dec 6.
Abstract | Full Citation | Find Related Articles | | Autier J, Escudier B, Wechsler J, et al.
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. [Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't]
Arch Dermatol 2008 Jul; 144(7):886-92.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Escudier B, Lassau N, Angevin E, et al.
Phase I Trial of Sorafenib in Combination with IFN {alpha}-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma. [Journal Article]
Clin Cancer Res 2007 Mar 15; 13(6):1801-9.
Abstract | Full Citation | Find Related Articles | | Lountzis NI, Maroon MS
Sorafenib-induced palmoplantar hyperkeratosis. [Journal Article]
J Drugs Dermatol 2008 Jun; 7(6):588-9.
Abstract | Full Citation | Find Related Articles | | Akaza H, Tsukamoto T, Murai M, et al.
Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Sorafenib in Japanese Patients with Advanced Renal Cell Carcinoma. [JOURNAL ARTICLE]
Jpn J Clin Oncol 2007 Oct 19.
Abstract | Full Citation | Find Related Articles | | Abou-Alfa GK, Schwartz L, Ricci S, et al.
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. [Journal Article]
J Clin Oncol 2006 Sep 10; 24(26):4293-300.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Ratain MJ, Eisen T, Stadler WM, et al.
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. [Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial]
J Clin Oncol 2006 Jun 1; 24(16):2505-12.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Escudier B, Eisen T, Stadler WM, et al.
Sorafenib in advanced clear-cell renal-cell carcinoma. [Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't]
N Engl J Med 2007 Jan 11; 356(2):125-34.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Chu D, Lacouture ME, Fillos T, et al.
Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis. [Journal Article]
Acta Oncol 2008; 47(2):176-86.
Abstract | Full Citation | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
